10-K: Neuraxis, Inc. Details Share Structure and Regulatory Landscape in 10-K Filing

Neuraxis, Inc.'s 10-K filing provides a comprehensive overview of its share structure, regulatory environment, and business operations, highlighting its focus on neuromodulation therapies.

Summary

• Neuraxis, Inc. has one class of securities registered under the Securities Exchange Act of 1934: common stock, with a par value of $0.001 per share.
• The company is authorized to issue up to 101,120,000 shares of capital stock, including 100,000,000 shares of common stock and 1,120,000 shares of preferred stock.
• Neuraxis's common stock trades on the NYSE American under the symbol NRXS.
• As of April 12, 2024, there were 6,594,897 shares of common stock issued and outstanding.
• The company's primary product, IB-Stim, is a percutaneous electrical nerve field stimulation (PENFS) system for patients 11-18 years old with functional abdominal pain associated with IBS.
• Neuraxis is also developing PENFS for other pediatric conditions, including chronic nausea, post-concussion syndrome, chemotherapy-induced nausea and vomiting, and cyclic vomiting syndrome.
• The company's intellectual property includes eight granted patents and nine pending patent applications in the U.S., as well as nine pending foreign patent applications.
• Neuraxis operates as a smaller reporting company and an emerging growth company, which allows for certain reduced disclosure obligations.
• The company is subject to extensive regulation by the FDA and other authorities, including requirements for premarket clearance, clinical trials, and post-market surveillance.
• Neuraxis is also subject to healthcare fraud and abuse laws, data privacy and security laws, and environmental regulations.
• The company relies on a single manufacturer for its IB-Stim device and is working to secure second-source suppliers.
• The company reported a net loss of $14,626,683 for the year ended December 31, 2023, and $4,780,061 for the year ended December 31, 2022.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has a strong product and patent portfolio, it faces significant financial challenges, including substantial losses and reliance on a single manufacturer. The company is also subject to extensive regulatory requirements and faces competition. The sentiment is neutral to slightly negative due to the financial losses and risks.

Positives

• Neuraxis has a first-to-market advantage with its IB-Stim device for pediatric IBS.
• The company has a strong portfolio of device and method patents.
• There are large market opportunities in the pediatric industry.
• Neuraxis has a strong pediatric pipeline with multiple clinical trials underway.
• The company has academic society support for its technology.
• The company has lower capital expenditures for first-line therapy.
• The company has strong clinical data from leading academic institutions.
• The company has a strong gross margin.
• The company has a direct sales force targeting children's hospitals and pediatric clinics.

Negatives

• The company has a history of incurring substantial operating losses.
• The company is dependent on a single manufacturer for its product.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company's near-term prospects are substantially dependent on obtaining regulatory approvals and commercializing its products.
• The company may not be able to compete with treatments now being marketed and developed by other companies.
• The company may not be successful in maintaining reimbursement codes necessary to facilitate accurate and timely billing for its products or physician services attendant to its products.
• The company may not be successful in achieving market acceptance of its products by healthcare professionals, patients and/or third-party payers in the timeframes it anticipates, or at all.

Risks

• The company's business and prospects depend entirely on its current product, IB-Stim.
• Clinical studies could be delayed or adversely affected by many factors, including difficulties in enrolling patients.
• The company may not be able to develop an adequate sales and marketing organization or contract with third parties to assist it.
• The company may not be successful in achieving market acceptance of its products.
• Failure to secure and maintain adequate coverage and reimbursement from third-party payers could reduce revenues.
• The company may depend on single-source suppliers for some of its components.
• The company currently does not own a manufacturing facility and relies on a sole manufacturer for the production of its product.
• The company may not be able to compete with treatments now being marketed and developed by other companies.
• The company has material weaknesses in its internal control over financial reporting.
• Product liability suits could be brought against the company due to alleged defective devices or for the misuse of its products.
• The company is increasingly dependent on information technology systems and is subject to privacy and security laws.
• The company may choose to, or may be required to, suspend, repeat or terminate its clinical studies if they are not conducted in accordance with regulatory requirements.
• The company is subject to extensive post-marketing regulation by the FDA and comparable authorities in other jurisdictions.
• The company may not be successful in maintaining reimbursement codes necessary to facilitate accurate and timely billing for its products or physician services attendant to its products.
• The company may not be able to compete with treatments now being marketed and developed, or which may be developed and marketed in the future by other companies.
• The company may fail to select or capitalize on the most scientifically, clinically or commercially promising or profitable indications or therapeutic areas for its product candidates.
• The company may not be able to maintain a listing of its common stock on NYSE American.
• The company does not expect to declare or pay dividends in the foreseeable future.
• Future issuances of the company's common stock or securities convertible into, or exercisable or exchangeable for, its common stock, or the expiration of lock-up agreements that restrict the issuance of new common stock or the trading of outstanding common stock, could cause the market price of its common stock to decline and would result in the dilution of your holdings.
• If the company's shares of common stock become subject to the penny stock rules, it would become more difficult to trade its shares.
• The company is subject to ongoing public reporting requirements that are less rigorous than Exchange Act rules for companies that are not emerging growth companies, and its stockholders could receive less information than they might expect to receive from more mature public companies.
• Because the company is a smaller reporting company, it may take advantage of certain scaled disclosures available to it, resulting in holders of its securities receiving less company information than they would receive from a public company that is not a smaller reporting company.

Future Outlook

The company seeks growth and expansion through the reinvestment of profits and does not anticipate paying dividends in the foreseeable future. The company expects to incur significant expenses and operating losses for the foreseeable future as it continues to pursue widespread insurance coverage of its IB-Stim device and seek FDA clearance of its device for other indications.

Management Comments

• The company believes that superior science and evidence-based research are necessary for adoption by the medical and scientific community.
• The company's mission is to provide solutions that create value and provide better and safer patient outcomes.
• The company believes in improving lives and minimizing suffering, particularly in the pediatric population.
• The company is focused on opportunities in the pediatrics industry, which has multi-billion-dollar market opportunities.

Industry Context

The document highlights the unmet need in the pediatric industry for effective treatments for functional abdominal pain disorders, including IBS. It positions IB-Stim as a non-drug alternative with clinical evidence and academic society support, contrasting it with off-label medications and limited access to psychological treatments. The company is also working to expand its pipeline to address other pediatric conditions.

Comparison to Industry Standards

• The document notes that the neurostimulation market is predominantly comprised of surgically implanted, invasive technologies, which are not directly competitive with Neuraxis's non-implanted technology.
• Several neurostimulation companies are large, publicly traded companies with easier access to capital and established product pipelines, while Neuraxis is a smaller company.
• The company's method patents protect access to the brain, particularly the limbic systems through branches of cranial nerves in the ear, which is a unique approach compared to other companies in the neuromodulation space.
• The company's focus on pediatric indications is a differentiator, as many competitors target adult populations.
• The company's clinical data, including a multicenter registry study, is presented as a strength compared to other treatments for pediatric pain associated with DGBIs.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in ongoing litigation related to claims of misrepresentation regarding the billing of the NeuroStim device.
• The company believes it has meritorious defenses and intends to defend the matters vigorously.

Related Party Transactions

• The company has demand notes receivable from two founding shareholders related to the sale of common stock on January 1, 2016.
• The company has loans payable to Christopher Robin Brown, one of its founders and a member of its board of directors, related to funding needs for operations.
• Mr. Watkins, Director, provided certain sales, marketing and commercialization consulting services to the Company prior to his appointment to the Board of Directors.
• John Seale, the company's former Chief Financial Officer, is also the managing partner of RBSK, which provides accounting services to the company.

Stakeholder Impact

• Shareholders may experience dilution from future issuances of common stock or securities convertible into common stock.
• Employees may be affected by changes in compensation or benefits.
• Customers (hospitals and clinics) may be affected by changes in pricing or reimbursement policies.
• Patients may benefit from the company's products, but may also be affected by changes in insurance coverage or access to treatment.
• Suppliers may be affected by changes in the company's manufacturing or supply chain.

Next Steps

• The company plans to extensively ramp-up its marketing efforts to patients and physicians as it gains additional indications.
• The company continues to work diligently with the American Academy of Pediatrics and other specialty medical societies on the pursuit of a Category I CPT Code for PENFS procedures.
• The company anticipates academic medical society support in the form of a position paper and an update to treatment guidelines to support the use of PENFS as a potential standard of care.
• The company will continue to actively leverage clinical evidence and peer-reviewed publications to expand patient access to IB-Stim technology.

Key Dates

Keywords

neuromodulation, IB-Stim, PENFS, pediatric, IBS, medical device, FDA, clinical trials, regulatory, patents, reimbursement, healthcare